TD Cowen analyst Boris Peaker lowered the firm’s price target on CTI BioPharma to $8 from $10 and keeps an Outperform rating on the shares. The analyst said we are updating our model and corresponding estimates as VONJO sales have been slower than initially anticipated.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTIC:
- Largest borrow rate increases among liquid names
- CTI BioPharma options imply 9.1% move in share price post-earnings
- CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results
- CTI BioPharma reports Q4 EPS (14c), consensus (10c)
Questions or Comments about the article? Write to editor@tipranks.com